The Role of Dr. Avi Weisfogel in the World of Sleep Medicine

Dr. Avi Weisfogel is an American general dentist and a guru in the management of sleep disorders. Dr. Weisfogel owns and supervises the daily management affairs of Dental Sleep Masters, Old Bridge Dental Care, and Owner Unlimited Sleep Patient. He did psychology at the well-regarded Rutgers University and dentistry at the revered New York University College.

Dr. Weisfogel’s career journey

Dr. Avi Weisfogel began his successful medical career as a dentist at the Old Bridge Dental Care. In this facility, he provided services, such as cosmetic dental surgeries, dental implants, Invisalign. He also handled dental anxiety and sufferers. For over ten years, he strived to bring smiles into the lives of people. On three consecutive years, he was named one of the best dentists. In 2012, Dr. Weisfogel instituted Owner Unlimited Sleep Patient, a company that he uses to hold seminars to teach his colleagues about sleep disorders. Among the topics he lectures on is how to serve sleep patients. He unveiled Dental Sleep Masters in 2014 to support his interests in exploring the world of sleep apnea. He also uses this company to conduct research and expand his knowledge about this condition.

Dr. Weisfogel’s thoughts on sleep apnea

According to Dr. Weisfogel, obstructive sleep apnea can affect anyone at any particular time. However, the predisposing factors revolve around excess weight and age. Based on Dr. Weisfogel findings, sleep apnea is associated with positioning of fat deposits. In most people with excess weight, fat accumulates in the waist and neck region, which presses the airway. Men and women with a neck larger than 16 and 17 inches respectively also suffer from obstructive sleep apnea due to constriction of the airway. Additionally, other people susceptible to this condition include patients with high blood pressure, diabetes, men over 40, and individuals with a history of smoking. Dr. Weisfogel also adds that children with enlarged tonsils and are obese are also at risk and read full article.

Regional marketing has helped Dr. Weisfogel grow his businesses. He tries to run his company’s with ease so that he can reach out to more people. He has established sleep labs that assist sleep apnea patients. Dr. Weisfogel also advocates for the use of dental appliances to bring relief to these patients. He prefers to read the Power of Now, and he is inspired by Steve Jobs’ attention to detail and ingenuity.

More visit:

Seattle Genetics – Company Working on Life Saving Cancer Therapeutics

Seattle Genetics is a company which has been making many life-saving cancer drugs from antibodies. The company is located in a Suburb of Seattle, and is traded on the Nasdaq. They also have 650 employees, and are working on cell-killing therapies. This is a safer alternative to traditional chemotherapy in order to avoid the cancer. Drugs are attached to antibodies, and released upon contact with cancer cells. The company’s focus is on linking drugs to antibodies with enzymes. The company also had to look for new toxins which it could attach to the antibodies which are in their pipeline. Seattle Genetics is instead working on a targeted antibody therapy which targets specific cancerous cells. Antibodies are being used rapidly, and represent a huge market in the pharmaceutical industry which is in the Billions of dollars, and the sales have been increasing rapidly.

The company filed for it’s IPO in 2001, and was the only biotech company at the time which filed an IPO but managed to raise $51 million in capital. This gave the company greater access to capital, and was financing yearly to ensure that the company was able to make money. The company is now very profitable due to it’s own revenues. The company’s stock price has gone up rapidly since the company has gone public.

The President of Seattle Genetics is Clay Siegall, a holder of a PhD in Genetics whom has also worked for Bristol-Meyers Squibb. He relocated to Seattle, and later on quit to pursue his passion for working with monoclonal antibodies. The company also discovered a lot of technology that they were able to license out to other companies, and began with $7 million in financing. It took approximately 9 months for the company to raise money from venture capitalists, and later on 3 months for the company to raise money from Bank of America following some successes. Clay Siegall is also on the Board of Directors at Siegall Genetics, Alder Biotherapeutics, and MiRNA Therapeutics, a company which is working on Micro RNA therapeutics.